Expert Interview
A Look at the Potential of cretostimogene grenadenorapvec in Intermediate-risk Non–Muscle Invasive Bladder Cancer ahead of its Phase 3 trial Data Readout
Ticker(s): CGONInstitution: Keck School of Medicine of the University of Southern California / Keck Medicine of USC
Professor of Clinical Urology (Clinical Scholar) and urologic oncologist at USC
Treats over 600 patients with NMIBC per year and manages a high-volume clinical practice focused on complex germ cell tumors, post-chemotherapy retroperitoneal lymph node dissection, advanced testicular cancer, bladder cancer, prostate cancer, and advanced kidney cancers with vena caval tumor thrombus involvement.
Primary research focus includes clinical trials in bladder and testicular cancers, perioperative pathway optimization following radical cystectomy and post-chemotherapy RPLND, development and use of serum and molecular biomarkers, and evaluation of functional outcomes following orthotopic urinary diversion.
In intermediate-risk NMIBC after tumor resection, how do you currently decide between surveillance alone versus intravesical therapy, and where do you see the biggest unmet need in this patient segment?
Added By: sara_adminAs you think about a Phase 3 study comparing cretostimogene grenadenorepvec vs surveillance, which efficacy endpoints (e.g., recurrence-free survival, time to high-grade recurrence, progression) would be most clinically meaningful to change practice in this setting?
Added By: sara_adminIf the study shows a statistically significant improvement over surveillance, what magnitude of benefit, and what safety/tolerability profile would be required for you to adopt this therapy in intermediate-risk patients?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
